<DOC>
	<DOCNO>NCT00310128</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , etoposide , methylprednisolone , cytarabine , cisplatin , work different way stop growth cancer cell , either kill cell stop dividing . Monoclonal antibody , rituximab yttrium Y 90 ibritumomab tiuxetan , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance without harm normal cell . Giving one drug ( combination chemotherapy ) together rituximab yttrium Y 90 ibritumomab tiuxetan may kill cancer cell . PURPOSE : This phase II trial study well give combination chemotherapy together rituximab yttrium Y 90 ibritumomab tiuxetan work treat patient relapsed refractory AIDS-related non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy Followed Rituximab Yttrium Y 90 Ibritumomab Tiuxetan Treating Patients With Relapsed Refractory AIDS-Related Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine overall survival rate one year patient relapse refractory AIDS-related non-Hodgkin 's lymphoma treat consolidation therapy comprise rituximab yttrium Y 90 ibritumomab tiuxetan ( radioimmunotherapy ) give induction therapy comprise etoposide , methylprednisolone , cytarabine , cisplatin ( ESHAP ) . - Describe toxicity profile radioimmunotherapy consolidation therapy , include change immunologic virologic parameter time , patient . - Determine overall disease-free survival patient receive ESHAP induction therapy follow radioimmunotherapy consolidation therapy . Secondary - Determine effect ESHAP induction therapy radioimmunotherapy consolidation therapy HIV-1 viral load , CD4 CD8 cell , quantitative immunoglobulin level patient concurrent highly active antiretroviral therapy ( HAART ) . - Determine objective response rate ( complete partial response ) patient treat regimen . - Determine toxicity ESHAP induction therapy patient . OUTLINE : This multicenter study . - Induction therapy : Patients receive ESHAP chemotherapy comprise etoposide IV 2 hour day 1-4 , methylprednisolone IV 15-30 minute day 1-5 , cisplatin IV continuously 96 hour day 1-4 , cytarabine IV 2 hour day 5 . Treatment repeat every 21-28 day 4 course absence disease progression unacceptable toxicity . Approximately 21-52 day completion ESHAP chemotherapy , patient proceed consolidation therapy . - Consolidation therapy : Patients receive radioimmunotherapy comprise rituximab IV 3-4 hour follow indium In 111 ibritumomab tiuxetan ( radioimaging ) IV 10 minute day 1 . Patients undergo imaging day 1 2 . If biodistribution acceptable , patient receive rituximab IV 3-4 hour follow yttrium Y 90 ibritumomab tiuxetan IV 10 minute day 8 . After complete study treatment , patient follow every 2 month 1 year every 6 month 2 year . PROJECTED ACCRUAL : A total 33 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Lymphoma , AIDS-Related</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically document Bcell nonHodgkin 's lymphoma , include follow histologic type : Follicular large Bcell lymphoma ( follicular , grade 3 ) Follicular mixed cell lymphoma ( follicular , grade 2 ) Diffuse mixed cell lymphoma Diffuse large Bcell lymphoma Immunoblastic lymphoma Burkitt Burkittlike lymphoma Anaplastic large cell lymphoma Primary effusion lymphoma All stag eligible Seropositive HIV approve test positive HIV1 RNA plasma anytime past Prior documentation HIV seropositivity allow Received 1 prior anthracyclinebased regimen curative intent No 1 prior regimen Measurable evaluable disease Evaluable disease define bidimensional measurement ( i.e. , gastric marrow involvement ) follow response diagnostic test , gallium scan , positron emission tomography ( PET ) image and/or bone marrow biopsy No primary CNS lymphoma Lymphomatous meningitis brain metastasis eligible provide measurable systemic lymphomatous disease also present Less 25 % bone marrow involvement lymphoma Concurrent effective highly active antiretroviral therapy ( HAART ) require study entry HIV viral load &lt; 100,000 copies/mL HAART use previously PATIENT CHARACTERISTICS : Karnofsky performance status 50100 % Bilirubin ≤ 2.0 mg/dL ( unless elevate due lymphomatous involvement liver biliary tract OR due HIV medication [ e.g. , indinavir atazanavir ] ) Creatinine &lt; 2.0 mg/dL ( &lt; 2.6 mg/dL due use tenofovir truvada ) OR creatinine clearance ≥ 60 mL/min Granulocyte count &gt; 1,000/mm^3 ( unless abnormal due lymphomatous involvement bone marrow ) Platelet count &gt; 75,000/mm^3 ( unless abnormal due lymphomatous involvement bone marrow HIVrelated thrombocytopenia ) No acute intercurrent infection may interfere study participation Mycobacterium avium allow No second active tumor except nonmelanomatous skin cancer , carcinoma situ cervix , Kaposi 's sarcoma require systemic chemotherapy Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception ≥ 6 month completion study treatment No serious , ongoing nonmalignant disease infection would compromise study objectives No antimurine antibody ( HAMA ) reactivity No history cutaneous mucocutaneous reaction prior rituximab administration No history cutaneous mucocutaneous reaction disease severe enough cause hospitalization inability eat ≥ 2 day PRIOR CONCURRENT THERAPY : See Disease Characteristics Fully recover toxicity associate prior surgery , radiotherapy , chemotherapy , immunotherapy Prior chronic therapy potentially myelosuppressive agent allow provide hematologic criterion meet study entry No radiotherapy within past 4 week , unless emergency condition secondary lymphoma ( i.e. , cord compression ) No anticancer therapy within past 3 week ( 6 week nitrosourea mitomycin C ) No rituximab within 6 week study radioimmunotherapy No investigational agent ( ) within past 4 week , unless antiretroviral agent available compassionate use basis No prior external beam radiotherapy &gt; 25 % active bone marrow ( involved field regional ) No major surgery , diagnostic surgery , within past 4 week No prior myeloablative therapy autologous bone marrow transplantation , peripheral blood stem cell rescue , fail stem cell collection No prior radioimmunotherapy No pegfilgrastim within 4 week study radioimmunotherapy No growth factor within 2 week study radioimmunotherapy No concurrent myelosuppressive antineoplastic agent receipt study radioimmunotherapy blood count recover No zidovudinecontaining regimen ( include lamivudine trizivir ) ≥ 2 month completion study radioimmunotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>AIDS-related diffuse large cell lymphoma</keyword>
	<keyword>AIDS-related peripheral/systemic lymphoma</keyword>
	<keyword>AIDS-related small noncleaved cell lymphoma</keyword>
	<keyword>AIDS-related diffuse mixed cell lymphoma</keyword>
	<keyword>AIDS-related immunoblastic large cell lymphoma</keyword>
	<keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>stage I grade 2 follicular lymphoma</keyword>
	<keyword>stage I grade 3 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>contiguous stage II adult Burkitt 's lymphoma</keyword>
	<keyword>noncontiguous stage II adult Burkitt 's lymphoma</keyword>
	<keyword>recurrent adult Burkitt 's lymphoma</keyword>
	<keyword>stage I adult Burkitt 's lymphoma</keyword>
	<keyword>stage III adult Burkitt 's lymphoma</keyword>
	<keyword>stage IV adult Burkitt 's lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>stage I adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage I adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>contiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage I adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
</DOC>